Last checked at 30 Jan 2017 10:50
Shield Therapeutics plc
("Shield" or the "Group")
Directorate and Secretarial Update
London, UK, 30 January 2017: Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on secondary care, announces the resignation of Richard Jones as a director and company secretary of the company on 27 January 2017.
The company had previously announced on 7 November 2016 that Richard Jones would leave the Group in early 2017 to pursue a new opportunity.
The company has appointed Capita Registrars Limited as company secretary from 27 January 2017.
- Ends -
For further information please contact:
Shield Therapeutics plc | +44 (0)20 7186 8500 |
Carl Sterritt, Chief Executive Officer
| |
Nominated Adviser and Broker Liberum Capital Limited Christopher Britton/Steve Pearce
| +44 (0)20 3100 2222 |
Financial PR Advisor Consilium Strategic Communications | +44 (0)20 3709 5700 shieldtherapeutics@consilium-comms.com |
Mary-Jane Elliott/Matthew Neal |
About Shield Therapeutics plc
Shield Therapeutics is a specialty pharmaceutical company focused on the commercialisation and development of late-stage, hospital-focused pharmaceuticals which address areas of unmet medical need. The Group has a marketed product, Feraccru®, for the treatment of iron deficiency anaemia (IDA) which has exclusive IP rights until 2034. In addition, the Group is developing PT20, a late-stage pharmaceutical for the treatment of systemic phosphate accumulation (hyperphosphatemia). Shield Therapeutics, headquartered in London, is listed on LSE's AIM under the ticker STX. For more information please visit www.shieldtx.com.